Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revive Therapeutics Ltd. C.RVV

Alternate Symbol(s):  RVVTF

Healthcare
Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics for rare disorders and infectious diseases. The Company is exploring the use of Bucillamine for the treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. Through its subsidiary, Psilocin Pharma Corp., the Company is... see more

Recent & Breaking News (CSE:RVV)

Revive Therapeutics Announces Publication Showing Bucillamine's Potential Impact on COVID-19 Omicron Variants

GlobeNewswire January 9, 2023

Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

GlobeNewswire January 5, 2023

Revive Therapeutics Announces Submission of Type C Meeting Request to FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

GlobeNewswire December 22, 2022

Revive Therapeutics Ltd. Expands Life Offering to Quebec

GlobeNewswire December 15, 2022

Revive Therapeutics (CSE:RVV) announces $5M private placement

John Ballem  December 1, 2022

Revive Therapeutics Ltd. Announces Offering of Up to $5 Million

GlobeNewswire November 30, 2022

Revive Therapeutics Announces Update for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

GlobeNewswire November 24, 2022

Revive Therapeutics Announces FDA Recommendation for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

GlobeNewswire November 22, 2022

Revive Therapeutics Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA

GlobeNewswire October 14, 2022

Revive Therapeutics (CSE:RVV) updates Bucillamine in treating COVID-19

Caroline Egan  October 6, 2022

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

GlobeNewswire October 6, 2022

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

GlobeNewswire September 28, 2022

Revive Therapeutics (CSE:RVV) updates phase I/II clinical study of oral psilocybin

John Ballem  September 16, 2022

Revive Therapeutics Provides Update on the Psilocybin Clinical Study for Methamphetamine Use Disorder and Oral Psilocybin Thin Film Strip Program

GlobeNewswire September 16, 2022

CSE Bulletin: INDEX - CSE 25 INDEX QUARTERLY REBALANCING

Newsfile September 15, 2022

Revive Therapeutics (CSE:RVV) submits amended Phase 3 COVID-19 study protocol to FDA

John Ballem  September 14, 2022

Revive Therapeutics Announces Submission of Amended Phase 3 COVID-19 Study Protocol to FDA

GlobeNewswire September 14, 2022

Update from Revive Therapeutics (CSE:RVV) on Phase 3 clinical trial for Bucillamine in COVID-19

John Ballem  August 16, 2022

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

GlobeNewswire August 16, 2022

Update from Revive Therapeutics (CSE:RVV) on Phase 3 clinical trial for Bucillamine in COVID-19

Dave Jackson July 25, 2022